Quick Answer
CHINA PHARMA HOLDINGS, INC. reported Total Revenue of $4.53 million for fiscal year 2024.
CHINA PHARMA HOLDINGS, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.53M -35.4% |
$7.01M -13.5% |
$8.10M -15.9% |
$9.64M -11.3% |
$10.87M -0.5% |
$10.92M -11.4% |
| Net Income | -$4.74M -53.8% |
-$3.08M +22.5% |
-$3.97M -16.9% |
-$3.40M -18.6% |
-$2.87M +86.2% |
-$20.70M -92.6% |
| Diluted EPS | -$0.27 +70.3% |
-$0.91 +75.9% |
-$3.78 -410.8% |
-$0.74 | — | — |
| Total Assets | $14.89M -9.6% |
$16.47M -7.4% |
$17.78M -21.5% |
$22.65M +7.3% |
$21.12M -5.0% |
$22.24M -51.0% |
| Cash and Equivalents | — | $1.42M -29.9% |
$2.03M -58.2% |
$4.86M +407.4% |
$957.7K -10.9% |
$1.07M -9.4% |
| Stockholders Equity | $7.75M +3.9% |
$7.45M +73.8% |
$4.29M -28.7% |
$6.02M -24.8% |
$8.00M -13.3% |
$9.24M -69.4% |
| R&D Expense | $283.9K +18.3% |
$240.1K +29.2% |
$185.9K -41.7% |
$319.0K -15.6% |
$378.0K +64.6% |
$229.6K +33.2% |
| Operating Income | -$4.59M -66.8% |
-$2.75M +22.5% |
-$3.55M -24.1% |
-$2.86M -10.9% |
-$2.58M +87.4% |
-$20.41M -95.3% |
| Gross Profit | -$1.99M -606.4% |
-$281.1K +43.1% |
-$493.9K -241.4% |
$349.3K -82.1% |
$1.95M +31.8% |
$1.48M -24.9% |
| Shares Outstanding | 32.62M +207.0% |
10.63M +609.2% |
1.50M -68.4% |
4.73M -89.6% |
45.58M +4.6% |
43.58M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $756.2K | -31.3% | -26.3% |
| Net Income | September 30, 2025 | -$651.5K | +41.7% | -23.3% |
| Diluted EPS | September 30, 2025 | -$0.17 | +73.8% | -6.3% |
| Total Assets | September 30, 2025 | $15.80M | +17.4% | +14.8% |
| Cash and Equivalents | September 30, 2025 | $267.6K | — | -57.3% |
| Stockholders Equity | September 30, 2025 | $8.31M | +27.4% | +28.7% |
| R&D Expense | September 30, 2025 | $40.3K | -54.0% | +92.4% |
| Operating Income | September 30, 2025 | -$628.1K | +42.1% | +3.7% |
| Gross Profit | September 30, 2025 | -$59.7K | +88.5% | +31.4% |
| Shares Outstanding | September 30, 2025 | 3.26M | -81.7% | -0.0% |
- CHINA PHARMA HOLDINGS, INC. reported Total Revenue of $4.53 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -35.4% in Total Revenue compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Net Income of -$4.74 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -53.8% in Net Income compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Diluted EPS of $0.27 per share (loss) for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed an increase of +70.3% in Diluted EPS compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Total Assets of $14.89 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -9.6% in Total Assets compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Cash and Equivalents of $1.42 million for fiscal year 2023.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -29.9% in Cash and Equivalents compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Stockholders Equity of $7.75 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed an increase of +3.9% in Stockholders Equity compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported R&D Expense of $283.9 thousand for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed an increase of +18.3% in R&D Expense compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Operating Income of -$4.59 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -66.8% in Operating Income compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Gross Profit of -$1.99 million for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -606.4% in Gross Profit compared to the prior fiscal year.
- CHINA PHARMA HOLDINGS, INC. reported Shares Outstanding of 32.62 million shares for fiscal year 2024.
- CHINA PHARMA HOLDINGS, INC. showed an increase of +207.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: